A U.S. Food & Drug Administration (FDA) panel recently recommended approval for AstraZeneca’s new monoclonal antibody, which supposedly protects infants and toddlers up to age 2 from respiratory syncytial virus (RSV). The drug, manufactured by AstraZeneca and Sanofi, is designed to be given to infants in a single shot at birth or just before the … Continue reading 12 Infants Die in Clinical Trial For RSV Injection Approved by FDA Panel